Introduction
From 1 September 2015, babies in the United Kingdom (UK) born on/after 1 July 2015 became eligible to receive the MenB vaccine, given at 2 and 4 months of age, with a booster at 12 months. 1 Early trials found a high prevalence of fever (over 38°C) in babies given the vaccine with other routine vaccines at 2 and 4 months. We used syndromic surveillance 2 data to assess whether there had been increased family doctor (general practitioner (GP)) consultations for fever in young infants following the introduction of the vaccine.
Methods
GP consultations for fever in infants aged under 1 year were extracted from The Phoenix Partnership (TPP) ResearchOne database (400 GP surgeries in England). 3 Data were stratified by week of age over the period 1 September 2015 to 30 November 2015 and 1 December 2015 to 29 February 2016. Fever consultation rates (per 100,000 registered practice population in the database) were compared to the same 3 month periods of the previous 5 years (2010-14) using incident rate ratios (IRR). Pre-and post-vaccination consultation rates were applied to the England 0-26 week population to estimate excess fever consultations.
Results
Between 1 September and 30 November 2015 the average daily fever consultation rate for infants aged 0-26 weeks was 4.72/100,000; the incident rate ratio was 1.46 (95% CI, 1.09-1.92). In the 7-10 week age group the average daily fever consultation rate was 7.79/100,000. The incidence rate was 2.68 times higher than in previous years (95% CI, 1.42-4.94).
Between 1 December 2015 and 29 February 2016 the average daily consultation rate for infants aged 0-26 weeks was 6.19/100,000. The incidence rate was 1.49 times higher than in the same 3 month period of previous years (95% CI, 1.16-1.90). In infants aged 7-10 weeks the average daily consultation rate was 8.44/100,000 and the incidence rate was 1.83 times higher than previous years (95% CI 1.03-3.16).
Between 1 September 2015 and 29 February 2016 there were an estimated additional 959 fever consultations for infants aged 0-26 weeks to English family doctors.
Conclusions
We have demonstrated an innovative use of syndromic surveillance to quickly and easily assess the impact on healthcare seeking behaviour for infants with fever following the introduction of a new vaccination into the routine vaccination programme in England. Our study provides reassurance that in infants aged 0-26 weeks there was no marked increase in consultations following the introduction of the new MenB vaccination. However, in some age groups below 0-26 weeks there was an increase in healthcare seeking behaviour for fever, in particular, the 7-10 week age group which includes infants aged 8 weeks receiving their first vaccination. Other age groups also demonstrated increased fever consultations during these two periods, albeit at less significant levels. We will analyse data for the full year from 1 September 2015 to further explore these findings, investigate potential confounders and assess trends since vaccine introduction.
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